Hospital
Portercare Adventist Health System
Portercare Adventist Health System was paid $2.45M by Medicaid between Jan 2018 and Dec 2024, across 73 billing codes. Its largest line is 11042, Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm — 21% of everything it billed.
33Billing provider infoPORTERCARE ADVENTIST HEALTH SYSTEM
DENVER, CO 80210
DENVER, CO 80210
33aNPI1801800594assigned 07/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.45M
24GClaims63,994
24DCodes billed73
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Colorado
Rank by total paid#23 of 51
Median peer was paid$1.24M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,864 | $303K | |
| 2019 | 7,746 | $332K | |
| 2020 | 8,305 | $408K | |
| 2021 | 8,143 | $395K | |
| 2022 | 8,682 | $317K | |
| 2023 | 13,815 | $468K | |
| 2024incomplete | 5,439 | $229K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 21% | 4,909 | 1,614 | $517K |
| 41899 | Unlisted procedure, dentoalveolar structures | 19% | 486 | 452 | $461K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 3,092 | 2,712 | $318K |
| S9480 | Intensive outpatient psychiatric services, per diem | 10% | 550 | 52 | $252K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.5% | 2,455 | 2,004 | $208K |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.4% | 777 | 651 | $158K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.0% | 1,153 | 995 | $98K |
| 80053 | Comprehensive metabolic panel | 3.7% | 6,389 | 5,444 | $91K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.5% | 1,807 | 1,135 | $62K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 2.3% | 2,914 | 782 | $55K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.6% | 465 | 365 | $39K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 83 | 79 | $28K |
61 more codes
| 99223 | Prolong inpt eval add15 m | 1.0% | 465 | $25K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,139 | $20K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,575 | $18K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 463 | $16K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 424 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,503 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 390 | $7K |
| 11045 | <1% | 358 | $7K | |
| 0002A | <1% | 90 | $6K | |
| 82105 | <1% | 200 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 92 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 53 | $3K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 18 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 17 | $3K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 13 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,018 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 648 | $2K |
| 0001A | <1% | 59 | $2K | |
| 80320 | <1% | 38 | $2K | |
| 85610 | <1% | 660 | $2K | |
| 84484 | <1% | 110 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 72 | $2K |
| 86850 | <1% | 80 | $2K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 50 | $1K |
| 73630 | <1% | 42 | $1K | |
| 97597 | <1% | 175 | $1K | |
| 83605 | <1% | 37 | $822.69 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 35 | $767.79 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 579 | $677.93 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 21 | $411.90 |
| 97116 | <1% | 30 | $294.89 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,122 | $294.45 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 14 | $289.80 |
| 86900 | <1% | 81 | $213.44 | |
| 80305 | <1% | 94 | $130.36 | |
| 83735 | <1% | 34 | $120.99 | |
| 86901 | <1% | 81 | $105.60 | |
| 80197 | <1% | 15 | $76.69 | |
| 71045 | Radiologic examination, chest; single view | <1% | 262 | $26.48 |
| 84100 | <1% | 34 | $21.61 | |
| 81001 | <1% | 38 | $18.28 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,932 | $9.25 |
| J3490 | Unclassified drugs | 0% | 3,723 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 610 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 515 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 62 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,111 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 80 | $0.00 |
| 83690 | 0% | 53 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 58 | $0.00 |
| 84703 | 0% | 52 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 112 | $0.00 |
| 82077 | 0% | 14 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 32 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 2,876 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 347 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 757 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 70 | $0.00 |
| 0753T | 0% | 121 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 107 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWHITLOCK, ANDREW (CFO)